血清EPCA-2检测在前列腺癌诊断中的临床研究  

Clinical significance of serum EPCA-2 in the diagnosis of prostate cancer

作　　者：罗振国[1] 王超[1] 陈向锋[2] 陶然[1] 韩旭[1] 王平[1] 

机构地区：[1]黑龙江省佳木斯大学附属第一医院泌尿外科,佳木斯154002 [2]上海交通大学医学院附属仁济医院泌尿外科

出　　处：《中国男科学杂志》2012年第8期22-24,共3页Chinese Journal of Andrology

基　　金：本研究受黑龙江省教育厅科技项目（12521544）资助

摘　　要：目的研究血清早期前列腺癌抗原-2（early prostate cancer antigen-2，EPCA-2）在前列腺癌诊断中的临床意义。方法收集良性前列腺增生（BPH）患者34例，前列腺癌患者22例，用酶联免疫法（ELISA）分别检测血清EPCA-2和前列腺特异性抗原（prostate-specific antigen，PSA）水平，然后进行统计学分析。结果（1）前列腺癌患者血清中EPCA-2和PSA水平均明显增高，与BPH组比较差异有统计学意义（P〈0．01）。（2）EPCA-2以30ng／ml为截点值诊断前列腺癌的特异性为91．2％，敏感性为95．4％，而PSA以4．0ng／ml作为截点值诊断的特异性为61．8％，敏感性为81．8％。结论EPCA-2可作为前列腺癌的肿瘤标记物，用于前列腺癌的诊断，较PSA具有更好的特异性和敏感性。Objective To investigate the clinical significance of serum EPCA-2 in the diagnosis of prostate cancer. Methods The levels of serum EPCA-2 and PSA in 34 patients with BPH and 22 patients with prostate cancer were detected respectively by ELISA. The data was analyzed by statistics methods. Results （1） Compared with that in patients with BPH, the levels of serum EPCA-2 and PSA in patients with prostate cancer increased significantly （ P〈0.01）. （2） Using a cutoff of 30ng/ml, EPCA-2 had a specificity of 91.2% and a sensitivity of 95.4% in differeiated diagnosis of BPH patients from prostate cancer patients, and using a cutoffof 4.0ngl/ml, PSA had atspecificity of 61.8% and a sensitivity of 81.8%. Conclusion EPCA-2 showed higher specificity and sensitivity than PSA in the diagnosis of prostate cancer, which indicated that it mignt be a better serum diagnosis biomarker.

关 键 词：早期前列腺癌抗原-2 核基质相关蛋白质类 前列腺肿瘤/诊断 

分 类 号：R737.25[医药卫生—肿瘤]